A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (CDX011-04)
Research Grant
Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Start Date
September 1, 2014
End Date
August 31, 2018
Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Start Date
September 1, 2014
End Date
August 31, 2018